Related references
Note: Only part of the references are listed.Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age
Vijay Yajnik et al.
ADVANCES IN THERAPY (2017)
Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab
Tim Wyant et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Self-reported Symptom Burden in Individuals with Inflammatory Bowel Disease
Dawn Farrell et al.
JOURNAL OF CROHNS & COLITIS (2016)
Genetic characteristics of inflammatory bowel disease in a Japanese population
Yuta Fuyuno et al.
JOURNAL OF GASTROENTEROLOGY (2016)
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers
Maria Rosario et al.
CLINICAL DRUG INVESTIGATION (2016)
Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort
Akbar K. Waljee et al.
PLOS ONE (2016)
The genetics of Crohn's disease and ulcerative colitis - status quo and beyond
David Ellinghaus et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2015)
Tacrolimus for the Treatment of Ulcerative Colitis
Katsuyoshi Matsuoka et al.
INTESTINAL RESEARCH (2015)
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Yasuo Suzuki et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Characteristics of Japanese inflammatory bowel disease susceptibility loci
Yoshiaki Arimura et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Immunosuppressive therapies for inflammatory bowel disease
Talia Zenlea et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Treatment Guidelines in Inflammatory Bowel Disease: The Japanese Perspectives
Katsuyoshi Matsuoka et al.
DIGESTIVE DISEASES (2013)
Antagonizing the α4β1 Integrin, but Not α4β7, Inhibits Leukocytic Infiltration of the Central Nervous System in Rhesus Monkey Experimental Autoimmune Encephalomyelitis
Krista G. Haanstra et al.
JOURNAL OF IMMUNOLOGY (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study
Asit Parikh et al.
INFLAMMATORY BOWEL DISEASES (2012)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease
Chadwick Williams et al.
Therapeutic Advances in Gastroenterology (2011)
Prevalence of ulcerative colitis and Crohn's disease in Japan
Keiko Asakura et al.
JOURNAL OF GASTROENTEROLOGY (2009)
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-alpha(4)beta(7) Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Dulce Soler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab
Maria del Pilar Martin et al.
ARCHIVES OF NEUROLOGY (2008)
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis
Bruce E. Sands et al.
GASTROENTEROLOGY (2008)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis
RB Sartor
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2006)
Brief report - Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
BK Kleinschmidt-DeMasters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Leukocytapheresis in ulcerative colitis: Results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment
K Sawada et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Share Paper
